Canine Cutaneous Mast Cell Tumours: Welfare and Surgical Management

Cutaneous mast cell tumours are the most common skin tumour in dogs, ranging from benign to aggressive, with surgical excision being the primary and most welfare-positive treatment approach.

Key Facts

Mast cell tumours account for approximately 20% of all canine skin tumours
They range from histological grade 1 (benign) to grade 3 (aggressive) with variable prognosis
Boxers, Bulldogs, Labradors, and Golden Retrievers are predisposed breeds
Wide surgical excision with 2cm margins provides the best outcome for low-grade tumours
Tyrosine kinase inhibitor drugs (toceranib, masitinib) improve outcomes for high-grade or metastatic disease

Welfare Considerations

Cutaneous mast cell tumour welfare depends on grade and treatment approach. Low-grade tumours treated with timely surgical excision carry an excellent prognosis and minimal welfare impact from the disease itself. Delayed treatment allows tumour degranulation events — which cause local histamine release producing severe swelling, ulceration, and systemic signs — causing significant acute welfare harm. High-grade tumours with metastatic potential cause progressive disease and require multimodal treatment. Regular skin examination for new masses enables early detection when treatment is most straightforward and welfare outcomes are best.

What You Can Do

Examine your dog's skin regularly and report any new lumps to your vet promptly
Request fine needle aspirate cytology for any suspicious skin mass to guide treatment planning
Pursue timely wide surgical excision for mast cell tumours to prevent degranulation-related welfare harm
Discuss tyrosine kinase inhibitor therapy with an oncologist for grade 3 or metastatic disease
Monitor for new primary tumours as recurrence at different sites occurs in predisposed breeds